175 related articles for article (PubMed ID: 35641554)
41. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
42. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
43. Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma.
Matei D; Hagag N; Madajewicz S; Chowhan N; Hentschel P; Avvento L; Burns P; Fiore J; Lipera W; Zarrabi H
Cancer; 1995 Oct; 76(8):1330-5. PubMed ID: 8620405
[TBL] [Abstract][Full Text] [Related]
44. A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin.
Arbuck SG; Douglass HO; Trave F; Rustum YM
NCI Monogr; 1987; (5):203-5. PubMed ID: 3501544
[TBL] [Abstract][Full Text] [Related]
45. Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid.
Turpin F; Lluch A; Closon MH; Gruia G; Llombart A; Fernandez R; Delgado FM; Biville F
Am J Clin Oncol; 1999 Apr; 22(2):196-8. PubMed ID: 10199461
[TBL] [Abstract][Full Text] [Related]
46. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.
Moliterni A; Tarenzi E; Capri G; Terenziani M; Bertuzzi A; Grasselli G; Agresti R; Piotti P; Greco M; Salvadori B; Pilotti S; Lombardi F; Valagussa P; Bonadonna G; Gianni L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-10-S17-14. PubMed ID: 9374085
[TBL] [Abstract][Full Text] [Related]
47. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
Machover D; Grison X; Goldschmidt E; Zittoun J; Lotz JP; Metzger G; Richaud J; Hannoun L; Marquet J; Guillot T
J Natl Cancer Inst; 1992 Mar; 84(5):321-7. PubMed ID: 1738182
[TBL] [Abstract][Full Text] [Related]
48. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial.
Deprés-Brummer P; Berthault-Cvitkovic F; Lĕvi F; Brienza S; Vannetzel JM; Jasmin C; Misset JL
J Infus Chemother; 1995; 5(3 Suppl 1):144-7. PubMed ID: 8528975
[TBL] [Abstract][Full Text] [Related]
49. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
50. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
51. Chronomodulated infusion of 5-fluorouracil, folinic acid and carboplatin in colorectal cancer: a pilot study.
Natoli C; Martino MT; Irtelli L; D'Ostilio N; Basilico L; Iacobelli S
Anticancer Res; 1995; 15(6B):2841-2. PubMed ID: 8669875
[TBL] [Abstract][Full Text] [Related]
52. Increased cytotoxicity of 5'-deoxy-5-fluorouridine by prolonged culture with folinic acid.
Matsuoka H; Furusawa M; Tomoda H; Seo Y; Sugimachi K
Anticancer Res; 1993; 13(6A):2201-6. PubMed ID: 8297134
[TBL] [Abstract][Full Text] [Related]
53. Rational basis for the metabolic modulation of 5-fluorouracil by leucovorin and interferon alpha.
Rustum YM
Br J Haematol; 1991 Oct; 79 Suppl 1():52-5. PubMed ID: 1931710
[TBL] [Abstract][Full Text] [Related]
54. Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Wendt TG; Hartenstein RC; Wustrow TP; Lissner J
J Clin Oncol; 1989 Apr; 7(4):471-6. PubMed ID: 2784493
[TBL] [Abstract][Full Text] [Related]
55. Cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid (CMFF) as first line chemotherapy for treatment of advanced breast cancer. A pilot study.
Glaubitz M; Günter HH; Lellé RJ; Lück HJ; Kühnle H
Eur J Gynaecol Oncol; 1995; 16(4):258-62. PubMed ID: 7556280
[TBL] [Abstract][Full Text] [Related]
56. Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
Bascioni R; Giorgi F; Silva RR; Acito L; Giustini L; De Signoribus G; Giuliodori L; Testa E
Breast Cancer Res Treat; 1997 Sep; 45(3):205-10. PubMed ID: 9386863
[TBL] [Abstract][Full Text] [Related]
57. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
58. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
[TBL] [Abstract][Full Text] [Related]
59. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Stöger H; Bauernhofer T; Schmid M; Ploner F; Moser R; Derstvenscheg E; Steindorfer P; Wilders-Truschnig M; Kuss I; Samonigg H
Cancer Chemother Pharmacol; 1994; 35(2):174-8. PubMed ID: 7987997
[TBL] [Abstract][Full Text] [Related]
60. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Zhang F; Yang Y; Smith T; Kau SW; McConathy JM; Esteva FJ; Kuerer HM; Symmans WF; Buzdar AU; Hortobagyi GN; Pusztai L
Cancer; 2003 Apr; 97(7):1758-65. PubMed ID: 12655533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
